Iroko Pharmaceuticals to receive $75 mln from OrbiMed

OrbiMed has agreed to provide a $75 million debt facility to Iroko Pharmaceuticals. MTS Securities, a subsidiary of MTS Health Partners, advised Iroko in the transaction. Based in Philadelphia, Iroko Pharmaceuticals is a global specialty pharmaceutical company focused on analgesia.

North AmericaUSBriefs